ADXS - Advaxis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.5100
-0.0800 (-2.23%)
At close: 4:00PM EDT

3.5100 0.00 (0.00%)
After hours: 5:49PM EDT

Stock chart is not supported by your current browser
Previous Close3.5900
Open3.5600
Bid3.4000 x 1100
Ask3.5900 x 1200
Day's Range3.4400 - 3.7368
52 Week Range2.7150 - 30.6000
Volume359,994
Avg. Volume718,964
Market Cap28.1M
Beta (3Y Monthly)5.42
PE Ratio (TTM)N/A
EPS (TTM)-8.7120
Earnings DateJun 5, 2019 - Jun 10, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.65
Trade prices are not sourced from all markets
  • Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know
    Zacks7 days ago

    Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know

    Advaxis (ADXS) closed the most recent trading day at $3.29, moving -0.3% from the previous trading session.

  • QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
    Zacks10 days ago

    QIAGEN Drives Molecular Diagnostics Suite With New Test Kit

    QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.

  • Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session
    Zacks16 days ago

    Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session

    Twist Bioscience (TWST) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Is Advaxis (ADXS) Outperforming Other Medical Stocks This Year?
    Zacks18 days ago

    Is Advaxis (ADXS) Outperforming Other Medical Stocks This Year?

    Is (ADXS) Outperforming Other Medical Stocks This Year?

  • Why Range Resources, Advaxis, and StoneCo Slumped Today
    Motley Fool22 days ago

    Why Range Resources, Advaxis, and StoneCo Slumped Today

    Equity offerings played a big role for two of these companies.

  • Benzinga23 days ago

    The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...

  • MarketWatch23 days ago

    Advaxis' stock plummets after public offering prices at deep discount

    Shares of Advaxis Inc. plummeted 25% to pace all premarket declines Wednesday, after the biotechnology company's public offering of shares priced at a deep discount. The company said its offering of 2.5 million shares to the public priced at $4.00 a share, or 32% below Tuesday's split-adjusted closing price of $5.90. A 1-for-15 reverse stock split went into effect on March 29. The company expects proceeds of about $10 million from the offering, which it intends to use to fund research and development of its product pipeline. Advaxis is focused on the development of immunotherapy products. The share offering comes after the stock has more than doubled year to date through Tuesday (up 107%), but has plunged 76% over the past 12 months. In comparison, the iShares Nasdaq Biotechnology ETF has gained 17% year to date and the S&P 500 has advanced 14%.

  • Business Wire23 days ago

    Advaxis Announces Pricing of Its Public Offering of Common Stock

    Advaxis, Inc. (ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $4.00 per share. The gross proceeds to Advaxis, Inc. from this offering are expected to be approximately $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses.

  • Business Wire23 days ago

    Advaxis, Inc. Announces Proposed Public Offering of Common Stock

    Advaxis, Inc. (ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it intends to offer and sell in an underwritten public offering shares of its common stock. Electronic copies of the preliminary prospectus supplement and prospectus may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 36th Floor, New York, NY 10022 or via telephone at 212-624-2060 or via email at prospectus@allianceg.com.

  • Advaxis Up on Positive Early-Stage Immunotherapy Study Data
    Zacks24 days ago

    Advaxis Up on Positive Early-Stage Immunotherapy Study Data

    Advaxis' (ADXS) immunotherapy candidate, ADXS-PSA, achieves favorable overall survival in mCRPC patients in combination with Merck's Keytruda.

  • Why Wynn Resorts, Advaxis, and Roku Jumped Today
    Motley Fool24 days ago

    Why Wynn Resorts, Advaxis, and Roku Jumped Today

    These stocks jumped on a strong start to the second quarter.

  • Why Advaxis Stock Skyrocketed 13.8% Today
    Motley Fool24 days ago

    Why Advaxis Stock Skyrocketed 13.8% Today

    The small-cap biotech reported encouraging news about its prostate cancer therapy.

  • Benzinga24 days ago

    Advaxis Shares Surge After Positive Clinical Trial Updates

    Advaxis, Inc. (NASDAQ: ADXS ) has announced a reverse stock split and clinical trial updates at the American Association of Cancer Research annual meeting in recent days. Investors have viewed the developments ...

  • ACCESSWIRE24 days ago

    Reverse Split and New Clinical Data, What's Next for Advaxis?

    NEW YORK, NY / ACCESSWIRE / April 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Biotech News: Why Advaxis Stock Is Soaring Today
    InvestorPlace24 days ago

    Biotech News: Why Advaxis Stock Is Soaring Today

    Advaxis stock is flying high Monday on news concerning a Phase1/2 study of ADXS-PSA.Source: Shutterstock ADXS-PSA is Advaxis' (NASDAQ:ADXS) Listeria monocytogenes-based immunotherapies. The drug is being evaluated for use on its own, as well as with Merck's (NYSE:MRK) anti-PD-1 therapy.The study of ADXS-PSA is broken up into two separate parts. The first is Part A, which focuses on the drug's effectiveness when used on its own. The second is Part B, which tests how it does alongside MRK's drug.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe important biotech news from Advaxis today has to do with the Part B portion of the study. New from this study shows that it is performing well when it comes to tolerability. There have been no major adverse events or additive toxicity.Another strong point from the Part B section of the study includes response from T-cell's to ADXS-PSA. There was a reaction from T-cells in 75% of subjects. It's also worth noting that antigen spreading was seen in 85% of subjects.More data from the ADXS-PSA study also finds patients taking part in the study to have a long survival rate. At the cutoff time for the data in this report, the median survival rate for patients in te study was 21.1 months. * The Elite 8 Stocks to Buy for Massive Outperformance Based on the prolonged survival data and strong safety profile to date, we believe that continued clinical development of ADXS-PSA in combination with KEYTRUDA® is warranted and represents a potentially significant opportunity for Advaxis," Kenneth Berlin, President and CEO of Advaxis, said in a statement.ADXS stock was up 16% as of noon Monday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Tech Stocks That Transformed Their Business * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos * 7 Weak Blue-Chip Stocks to Trim Immediately As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Biotech News: Why Advaxis Stock Is Soaring Today appeared first on InvestorPlace.

  • Business Wire25 days ago

    ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced updated data from the Phase 1/2 KEYNOTE-046 study in metastatic, castration-resistant prostate cancer (mCRPC). This trial is being conducted in conjunction with Merck (known as MSD outside the U.S. and Canada) and is evaluating ADXS-PSA, one of Advaxis’ Listeria monocytogenes (Lm)-based immunotherapies, alone and in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

  • Benzinga27 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

    Biotech stocks have managed to end the quarter in the green, supported in part by the broader market sentiment and some company-specific catalytic events. Curis, Inc. (NASDAQ: CRIS ) and PhaseBio Pharmaceuticals ...

  • Business Wire27 days ago

    Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-NEO data in a poster discussion entitled “Safety and Immunogenicity of a Personalized Neoantigen-Listeria Vaccine in Cancer Patients” at the American Association for Cancer Research (AACR) Annual Meeting underway in Atlanta. The discussion will be held on Sunday, March 31, 2019 from 1:00-5:00 p.m. ET and will be led by J. Randolph Hecht, M.D., Professor of Clinical Medicine, David Geffen School of Medicine at UCLA and Director of the UCLA Gastrointestinal Oncology Program. ADXS-NEO is a live, attenuated Listeria monocytogenes (Lm) immunotherapy, using personalized antigen delivery based on whole-exome sequencing of a patient’s tumor to identify personal neoantigens.

  • Business Wire28 days ago

    Advaxis Announces Reverse Stock Split

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that its Board of Directors has approved a one-for-fifteen (1-for-15) reverse stock split of its common stock that will become effective tomorrow, March 29, 2019, upon the filing of a Certificate of Amendment to its Certificate of Incorporation with the Secretary of the State of Delaware. Beginning on March 29, 2019, Advaxis’ common stock will trade on the Nasdaq Global Select Market on a reverse split-adjusted basis under the new CUSIP number 007624307. As previously disclosed, at the Company’s Annual Meeting of Stockholders held on February 21, 2019, Advaxis’ stockholders approved a proposal authorizing the Company’s Board of Directors to effect a reverse stock split by a ratio of not less than one-for-ten (1-for-10) and not more than one-for-twenty-five (1-for-25).

  • Top Ranked Momentum Stocks to Buy for March 28th
    Zacks29 days ago

    Top Ranked Momentum Stocks to Buy for March 28th

    Top Ranked Momentum Stocks to Buy for March 28th

  • Business Wirelast month

    Advaxis Granted U.S. Patent Relating to Axalimogene Filolisbac

    Advaxis, Inc. (ADXS) (the Company), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the U.S. Patent and Trademark Office has granted patent number 10,189,885 titled “Non-Hemolytic LLO Fusion Proteins and Methods of Utilizing Same.” This composition-of-matter patent extends protection for axalimogene filolisbac (AXAL) through March 2028. “We are pleased to receive another patent to further expand our robust intellectual property portfolio of more than 400 issued or pending patents worldwide,” said Robert G. Petit, Ph.D., Chief Scientific Officer of Advaxis.

  • Has Advaxis (ADXS) Outpaced Other Medical Stocks This Year?
    Zackslast month

    Has Advaxis (ADXS) Outpaced Other Medical Stocks This Year?

    Is (ADXS) Outperforming Other Medical Stocks This Year?

  • ACCESSWIRElast month

    These Four Healthcare Stocks Are Making Moves on Wednesday

    CORAL GABLES, FL / ACCESSWIRE / March 13, 2019 / The healthcare stock market has managed to attract significant attention in the initial months of 2019 as a result of healthcare companies demonstrating to investors and consumers their commitment to the future of the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NVAX), Advaxis Inc (ADXS), and MannKind Corporation (MNKD) are 4 healthcare companies raising the bar on Wednesday. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care.

  • Seres Therapeutics (MCRB) in Focus: Stock Moves 6.7% Higher
    Zackslast month

    Seres Therapeutics (MCRB) in Focus: Stock Moves 6.7% Higher

    Seres Therapeutics (MCRB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Associated Presslast month

    Advaxis: Fiscal 1Q Earnings Snapshot

    On a per-share basis, the Princeton, New Jersey-based company said it had profit of 18 cents. Earnings, adjusted for non-recurring gains, came to 15 cents per share. The biotechnology company posted revenue ...